144 related articles for article (PubMed ID: 38402087)
21. Impact of signal intensity normalization of MRI on the generalizability of radiomic-based prediction of molecular glioma subtypes.
Foltyn-Dumitru M; Schell M; Rastogi A; Sahm F; Kessler T; Wick W; Bendszus M; Brugnara G; Vollmuth P
Eur Radiol; 2024 Apr; 34(4):2782-2790. PubMed ID: 37672053
[TBL] [Abstract][Full Text] [Related]
22. A radiomics model based on DCE-MRI and DWI may improve the prediction of estimating IDH1 mutation and angiogenesis in gliomas.
Wang J; Hu Y; Zhou X; Bao S; Chen Y; Ge M; Jia Z
Eur J Radiol; 2022 Feb; 147():110141. PubMed ID: 34995947
[TBL] [Abstract][Full Text] [Related]
23. Radiomics risk score may be a potential imaging biomarker for predicting survival in isocitrate dehydrogenase wild-type lower-grade gliomas.
Park CJ; Han K; Kim H; Ahn SS; Choi YS; Park YW; Chang JH; Kim SH; Jain R; Lee SK
Eur Radiol; 2020 Dec; 30(12):6464-6474. PubMed ID: 32740813
[TBL] [Abstract][Full Text] [Related]
24. Qualitative and Quantitative MRI Analysis in IDH1 Genotype Prediction of Lower-Grade Gliomas: A Machine Learning Approach.
Cao M; Suo S; Zhang X; Wang X; Xu J; Yang W; Zhou Y
Biomed Res Int; 2021; 2021():1235314. PubMed ID: 33553421
[TBL] [Abstract][Full Text] [Related]
25. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
26. Diffusion tensor imaging radiomics in lower-grade glioma: improving subtyping of isocitrate dehydrogenase mutation status.
Park CJ; Choi YS; Park YW; Ahn SS; Kang SG; Chang JH; Kim SH; Lee SK
Neuroradiology; 2020 Mar; 62(3):319-326. PubMed ID: 31820065
[TBL] [Abstract][Full Text] [Related]
27. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
[TBL] [Abstract][Full Text] [Related]
28. Radiomics-based machine learning methods for isocitrate dehydrogenase genotype prediction of diffuse gliomas.
Wu S; Meng J; Yu Q; Li P; Fu S
J Cancer Res Clin Oncol; 2019 Mar; 145(3):543-550. PubMed ID: 30719536
[TBL] [Abstract][Full Text] [Related]
29. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas.
Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK
Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770
[TBL] [Abstract][Full Text] [Related]
30. Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas.
Zhang B; Chang K; Ramkissoon S; Tanguturi S; Bi WL; Reardon DA; Ligon KL; Alexander BM; Wen PY; Huang RY
Neuro Oncol; 2017 Jan; 19(1):109-117. PubMed ID: 27353503
[TBL] [Abstract][Full Text] [Related]
31. MRI Features May Predict Molecular Features of Glioblastoma in
Park CJ; Han K; Kim H; Ahn SS; Choi D; Park YW; Chang JH; Kim SH; Cha S; Lee SK
AJNR Am J Neuroradiol; 2021 Mar; 42(3):448-456. PubMed ID: 33509914
[TBL] [Abstract][Full Text] [Related]
32. Automated machine learning to predict the co-occurrence of isocitrate dehydrogenase mutations and O
Zhang S; Sun H; Su X; Yang X; Wang W; Wan X; Tan Q; Chen N; Yue Q; Gong Q
J Magn Reson Imaging; 2021 Jul; 54(1):197-205. PubMed ID: 33393131
[TBL] [Abstract][Full Text] [Related]
33. Peritumoral Radiomics for Identification of Telomerase Reverse Transcriptase Promoter Mutation in Patients With Glioblastoma Based on Preoperative MRI.
Zhang H; Zhou B; Zhang H; Zhang Y; Lei Y; Huang B
Can Assoc Radiol J; 2024 Feb; 75(1):143-152. PubMed ID: 37552107
[No Abstract] [Full Text] [Related]
34. Characteristics of the isocitrate dehydrogenase gene and telomerase reverse transcriptase promoter mutations in gliomas in Chinese patients.
Qu CX; Ji HM; Shi XC; Bi H; Zhai LQ; Han DW
Brain Behav; 2020 Apr; 10(4):e01583. PubMed ID: 32146731
[TBL] [Abstract][Full Text] [Related]
35. Natural language processing to predict isocitrate dehydrogenase genotype in diffuse glioma using MR radiology reports.
Kim M; Ong KT; Choi S; Yeo J; Kim S; Han K; Park JE; Kim HS; Choi YS; Ahn SS; Kim J; Lee SK; Sohn B
Eur Radiol; 2023 Nov; 33(11):8017-8025. PubMed ID: 37566271
[TBL] [Abstract][Full Text] [Related]
36. Using radiomics based on multicenter magnetic resonance images to predict isocitrate dehydrogenase mutation status of gliomas.
Liu Y; Zheng Z; Wang Z; Qian X; Yao Z; Cheng C; Zhou Z; Gao F; Dai Y
Quant Imaging Med Surg; 2023 Apr; 13(4):2143-2155. PubMed ID: 37064376
[TBL] [Abstract][Full Text] [Related]
37. TERT promoter mutated WHO grades II and III gliomas are located preferentially in the frontal lobe and avoid the midline.
Sun ZL; Chan AK; Chen LC; Tang C; Zhang ZY; Ding XJ; Wang Y; Sun CR; Ng HK; Yao Y; Zhou LF
Int J Clin Exp Pathol; 2015; 8(9):11485-94. PubMed ID: 26617880
[TBL] [Abstract][Full Text] [Related]
38. Amide proton transfer-weighted imaging and derived radiomics in the classification of adult-type diffuse gliomas.
Wu M; Jiang T; Guo M; Duan Y; Zhuo Z; Weng J; Xie C; Sun J; Li J; Cheng D; Liu X; Du J; Zhang X; Zhang Y; Liu Y
Eur Radiol; 2024 May; 34(5):2986-2996. PubMed ID: 37855851
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic accuracy and potential covariates for machine learning to identify IDH mutations in glioma patients: evidence from a meta-analysis.
Zhao J; Huang Y; Song Y; Xie D; Hu M; Qiu H; Chu J
Eur Radiol; 2020 Aug; 30(8):4664-4674. PubMed ID: 32193643
[TBL] [Abstract][Full Text] [Related]
40. Predicting TERT promoter mutation status using
Yamashita K; Hatae R; Kikuchi K; Kuga D; Hata N; Yamamoto H; Obara M; Yoshimoto K; Ishigami K; Togao O
Neuroradiology; 2023 Aug; 65(8):1205-1213. PubMed ID: 37308686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
